lixisenatide + thiazolidinedione

Lixisenatide + thiazolidinedione is a combination therapy composed of two pharmacological agents used in the management of type 2 diabetes mellitus. Lixisenatide is a synthetic analog of exendin-4 and acts as a short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA). Its mechanism involves stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon secretion, and delaying gastric emptying, which helps lower both fasting and postprandial blood glucose levels. Thiazolidinediones are a class of oral antidiabetic drugs that act as agonists at peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity, especially in adipose tissue, and reducing circulating free fatty acids, which further improves glycemic control. The combination offers a complementary approach: lixisenatide primarily targets postprandial hyperglycemia, while thiazolidinedione improves insulin sensitivity and basal glycemia. Combination therapy has shown improved glycemic and cardiovascular outcomes compared to monotherapies, and lixisenatide has been shown to mitigate adverse cardiovascular effects sometimes associated with thiazolidinediones[1][2][3][5].